Anupam Rasayan signs MoU with 3xper Innoventure for new age pharma molecules
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
The VITA-FAST tokens have been met with overwhelming interest
The zero-observation outcome reflects the company's robust quality management systems and commitment to excellence in its operations.
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
Investment will help fuel international partnerships, grow IGX Platform functionality, and diversify proposition with new generative AI solutions
The €70 million investment will allow the large-scale manufacturing of high-purity reagents for quality control and testing for biopharma customers, increasing annual output by several thousand tons
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Granules India sponsored an initiative to ignite a drug-free revolution and contribute towards an empowered society
Ensitrelvir is an oral antiviral that suppresses the replication of SARS-CoV-2 by selectively inhibiting the viral 3CL protease.
Subscribe To Our Newsletter & Stay Updated